Search

Your search keyword '"Fracchiolla, Nicola Stefano"' showing total 226 results
Start Over Author "Fracchiolla, Nicola Stefano"
226 results on '"Fracchiolla, Nicola Stefano"'

1. Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group

Author

Forghieri, Fabio, Cordella, Stefano, Marchesi, Francesco, Itri, Federico, Del Principe, Maria Ilaria, Cavalieri, Elena, Pasciolla, Crescenza, Bonanni, Matteo, Criscuolo, Marianna, Fiorentini, Alessandro, Guolo, Fabio, Buquicchio, Caterina, Prezioso, Lucia, Delia, Mario, Melillo, Lorella, Audisio, Ernesta, Zannier, Maria Elena, Cerchione, Claudio, Dargenio, Michelina, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Pezone, Sara, Perruccio, Katia, Santoni, Adele, Candoni, Anna, Vignetti, Marco, Luppi, Mario, Pagano, Livio, and Busca, Alessandro

Published
2024
Full Text
View/download PDF

2. Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax.

Author

Cordella, Stefano, Giusti, Davide, De Bellis, Eleonora, Dargenio, Michelina, Creti', Federica, Lazzarotto, Davide, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Piccini, Matteo, Forghieri, Fabio, Pagano, Livio, and Candoni, Anna

Subjects
DISEASE risk factors, CHRONIC obstructive pulmonary disease, BIOMARKERS, ACUTE myeloid leukemia, MYELOPROLIFERATIVE neoplasms
Abstract

A study published in the journal Hematological Oncology analyzed the outcomes of 263 patients with acute myeloid leukemia (AML) who were treated with hypomethylating agents (HMAs) and venetoclax. The study aimed to identify simple baseline predictors of overall survival (OS) in this patient population. The results showed that secondary AML and early infection were independent predictors of poor survival. The study proposed a predictive OS score based on these two parameters, which could help stratify patients and personalize their care. However, further research is needed to validate these findings. [Extracted from the article]

Published
2024
Full Text
View/download PDF

3. Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy

Author

Efficace, Fabio, Platzbecker, Uwe, Breccia, Massimo, Cottone, Francesco, Carluccio, Paola, Salutari, Prassede, Di Bona, Eros, Borlenghi, Erika, Autore, Francesco, Levato, Luciano, Finizio, Olimpia, Mancini, Valentina, D'Ardia, Stefano, Schlenk, Richard F., Melillo, Lorella, Fumagalli, Monica, Fiedler, Walter, Beltrami, Germana, Fracchiolla, Nicola Stefano, Bernardi, Massimo, Fazi, Paola, Annibali, Ombretta, Mayer, Karin, Voso, Maria Teresa, and Vignetti, Marco

Published
2021
Full Text
View/download PDF

4. Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Arena, Valentina, Palmieri, Raffaele, Filì, Carla, Carella, Angelo Michele, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Curti, Antonio, Luppi, Mario, Ingrosso, Claudia, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Mulè, Antonino, Tafuri, Agostino, Cudillo, Laura, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Trisolini, Silvia Maria, Alati, Caterina, La Sala, Edoardo, Maurillo, Luca, Del Principe, Maria Ilaria, Irno Consalvo, Maria Antonietta, Divona, Maria Domenica, Ottone, Tiziana, Cerretti, Raffaella, Sconocchia, Giuseppe, Voso, Maria Teresa, Fazi, Paola, Vignetti, Marco, and Buccisano, Francesco

Published
2024
Full Text
View/download PDF

5. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

Author

Rossi, G, Borlenghi, E, Zappasodi, P, Lussana, F, Bernardi, M, Basilico, C, Molteni, A, Lotesoriere, I, Turrini, M, Frigeni, M, Fumagalli, M, Cozzi, P, Gigli, F, Cattaneo, C, Fracchiolla, N, Riva, M, Martini, G, Mancini, V, Cairoli, R, Todisco, E, Rossi, Giuseppe, Borlenghi, Erika, Zappasodi, Patrizia, Lussana, Federico, Bernardi, Massimo, Basilico, Claudia, Molteni, Alfredo, Lotesoriere, Ivana, Turrini, Mauro, Frigeni, Marco, Fumagalli, Monica, Cozzi, Paola, Gigli, Federica, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Riva, Marta, Martini, Gianluca, Mancini, Valentina, Cairoli, Roberto, Todisco, Elisabetta, Rossi, G, Borlenghi, E, Zappasodi, P, Lussana, F, Bernardi, M, Basilico, C, Molteni, A, Lotesoriere, I, Turrini, M, Frigeni, M, Fumagalli, M, Cozzi, P, Gigli, F, Cattaneo, C, Fracchiolla, N, Riva, M, Martini, G, Mancini, V, Cairoli, R, Todisco, E, Rossi, Giuseppe, Borlenghi, Erika, Zappasodi, Patrizia, Lussana, Federico, Bernardi, Massimo, Basilico, Claudia, Molteni, Alfredo, Lotesoriere, Ivana, Turrini, Mauro, Frigeni, Marco, Fumagalli, Monica, Cozzi, Paola, Gigli, Federica, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Riva, Marta, Martini, Gianluca, Mancini, Valentina, Cairoli, Roberto, and Todisco, Elisabetta

Abstract

A retrospective survey was conducted in hematologic centres of the Rete Ematologica Lombarda (REL) on 529 older AML patients seen between 2020–2022. Compared to 2008–2016, the use of intensive chemotherapy (ICT) decreased from 40% to 18.1% and of hypomethylating agents (HMAs) from 19.5% to 13%, whereas the combination of Venetoclax/HMA, initially not available, increased from 0% to 36.7%. Objective treatment-specific fitness criteria proposed by SIE/SIES/GITMO in 2013 allow an appropriate choice between ICT and HMAs by balancing their efficacy and toxicity. Venetoclax/HMA, registered for patients unfit to ICT, has a unique toxicity profile because of prolonged granulocytopenia and increased infectious risk. Aiming at defining specific fitness criteria for the safe use of Venetoclax/HMA, a preliminary investigation was conducted among expert REL hematologists, asking for modifications of SIE/SIES/GITMO criteria they used to select candidates for Venetoclax/HMA. While opinions among experts varied, a general consensus emerged on restricting SIE/SIES/GITMO criteria for ICT-unfit patients to an age limit of 80–85, cardiac function > 40%, and absence of recurrent lung infections, bronchiectasis, or exacerbating COPD. Also, the presence of an adequate caregiver was considered mandatory. Such expert opinions may be clinically useful and may be considered when treatment-specific fitness criteria are updated to include Venetoclax/HMA.

Published
2024

6. Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission †

Author

Candoni, Anna, Chiusolo, Patrizia, Lazzarotto, Davide, Sartor, Chiara, Dargenio, Michelina, Chiaretti, Sabina, Skert, Cristina, Giglio, Fabio, Trappolini, Silvia, Fracchiolla, Nicola Stefano, Medici, Sara, Bresciani, Paola, Cuoghi, Angela, and Papayannidis, Cristina

Subjects
THERAPEUTIC use of antineoplastic agents, HEMATOPOIETIC stem cell transplantation, CANCER relapse, PATIENT safety, PROTEIN-tyrosine kinase inhibitors, SCIENTIFIC observation, DISEASE remission, HOMOGRAFTS, RETROSPECTIVE studies, DESCRIPTIVE statistics, STRUCTURED treatment interruption, CHROMOSOMES, DRUG efficacy, RESEARCH, LYMPHOBLASTIC leukemia, PROGRESSION-free survival, SURVIVAL analysis (Biometry), DRUG tolerance
Abstract

Simple Summary: The use of pre-emptive and prophylactic tyrosine kinase inhibitors (TKIs) after allogeneic hematopoietic stem cell transplantation (Allo-SCT) remains highly heterogeneous and very little is known about the use of third generation TKIs in this context. In this paper, we analyze the feasibility of maintenance with ponatinib administered after Allo-SCT to prevent cytologic relapse in a population of 48 patients with Philadelphia-positive acute lymphoblastic leukemia undergoing transplant while in complete cytologic remission. Although with the caution of the retrospective data, our analysis supports the feasibility of a ponatinib maintenance strategy after Allo-SCT, resulting in a low rate of discontinuation due to toxicity and a high probability of survival and relapse-free survival, particularly in the prophylactic group. In the majority of cases where a daily dose of 45 mg was started a dose reduction to 30–15 mg/day was required, which may be the appropriate dose to balance efficacy and tolerability. The administration of TKIs after Allo-SCT in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) remains controversial, and the TKI approach (prophylactic, pre-emptive or salvage) is still heterogeneous in transplant centers. In this context, very little is known about the feasibility and safety of third-generation TKIs. In this paper, we analyze the efficacy and safety of ponatinib (PONA) administered after Allo-SCT to prevent cytologic relapse of Ph + ALL. This is a multicenter observational study including 48 patients (pts) with Ph + ALL (median age 49 years) who received PONA after Allo-SCT while in complete cytological remission (cCR); 26 (54%) had positive minimal residual disease (MRD pos) before Allo-SCT. PONA was administered after Allo-SCT prophylactically (starting with MRD neg) in 26 pts or pre-emptively (starting with MRD pos post-SCT and without hematological relapse) in 22 pts. Patients treated prophylactically with PONA started treatment earlier, at a median of 4.3 months (range 1.5–6) after Allo-SCT, than those treated pre-emptively, who started PONA at a median of 7.4 months (range 2–63) after Allo-SCT (p = 0.01). The median starting dose of PONA was 30 mg/day (range 15–45). A dose reduction was required in 10/48 (21%) of cases, but a permanent discontinuation of PONA, due to toxicity, was required in only 5/48 pts (10.5%). No deaths due to PONA-related adverse events (AEs) were reported. The median follow-up time after Allo-SCT was 34 months (range 7.7–118). At the last follow-up, the median duration of PONA therapy was 22 months (range 2–100). The 5-year OS and RFS after Allo-SCT were 92% and 71%, respectively. The 5-year RFS after Allo-SCT of pts who received PONA prophylaxis was 95%, and it was 57% for those who received PONA pre-emptively (log-rank p = 0.02). In conclusion, this multicenter analysis of 48 patients with Ph + ALL undergoing Allo-SCT while in CcR, although with the caution of the retrospective data, supports the feasibility of PONA maintenance strategy after Allo-SCT with a low rate of discontinuations (10.5%) due to PONA-related AE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

Author

Rossi, Giuseppe, primary, Borlenghi, Erika, additional, Zappasodi, Patrizia, additional, Lussana, Federico, additional, Bernardi, Massimo, additional, Basilico, Claudia, additional, Molteni, Alfredo, additional, Lotesoriere, Ivana, additional, Turrini, Mauro, additional, Frigeni, Marco, additional, Fumagalli, Monica, additional, Cozzi, Paola, additional, Gigli, Federica, additional, Cattaneo, Chiara, additional, Fracchiolla, Nicola Stefano, additional, Riva, Marta, additional, Martini, Gianluca, additional, Mancini, Valentina, additional, Cairoli, Roberto, additional, and Todisco, Elisabetta, additional

Published
2024
Full Text
View/download PDF

9. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Author

Venditti, Adriano, Piciocchi, Alfonso, Candoni, Anna, Melillo, Lorella, Calafiore, Valeria, Cairoli, Roberto, de Fabritiis, Paolo, Storti, Gabriella, Salutari, Prassede, Lanza, Francesco, Martinelli, Giovanni, Luppi, Mario, Mazza, Patrizio, Martelli, Maria Paola, Cuneo, Antonio, Albano, Francesco, Fabbiano, Francesco, Tafuri, Agostino, Chierichini, Anna, Tieghi, Alessia, Fracchiolla, Nicola Stefano, Capelli, Debora, Foà, Robin, Alati, Caterina, La Sala, Edoardo, Fazi, Paola, Vignetti, Marco, Maurillo, Luca, Buccisano, Francesco, Del Principe, Maria Ilaria, Irno-Consalvo, Maria, Ottone, Tiziana, Lavorgna, Serena, Voso, Maria Teresa, Lo-Coco, Francesco, Arcese, William, and Amadori, Sergio

Published
2019
Full Text
View/download PDF

10. Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study

Author

Fracchiolla, Nicola Stefano, primary, Sciumè, Mariarita, additional, Papayannidis, Cristina, additional, Vitale, Antonella, additional, Chiaretti, Sabina, additional, Annunziata, Mario, additional, Giglio, Fabio, additional, Salutari, Prassede, additional, Forghieri, Fabio, additional, Lazzarotto, Davide, additional, Lunghi, Monia, additional, Imovilli, Annalisa, additional, Scappini, Barbara, additional, Bonifacio, Massimiliano, additional, Dargenio, Michelina, additional, Gurrieri, Carmela, additional, Todisco, Elisabetta, additional, Defina, Marzia, additional, Del Principe, Maria Ilaria, additional, Zappasodi, Patrizia, additional, Cerrano, Marco, additional, Santoro, Lidia, additional, Tagliaferri, Elena, additional, Barozzi, Enrico, additional, De Roberto, Pasquale, additional, Canzi, Marta, additional, Buzzatti, Elisa, additional, Sartor, Chiara, additional, Passamonti, Francesco, additional, Foà, Robin, additional, and Curti, Antonio, additional

Published
2023
Full Text
View/download PDF

11. PB2586: PASSIVE PREEXPOSURE IMMUNIZATION BY TIXAGEVIMAB/CILGAVIMAB IN COVID 19 INFECTED HEMATOLOGICAL MALIGNANCY OF EPICOVIDHEA SURVEY

Author

Buquicchio, Caterina, primary, Salmanton-García, Jon, additional, Marchesi, Francesco, additional, Itri, Federico, additional, Besson, Caroline, additional, Martín-Pérez, Sonia, additional, Dávila-Valls, Julio, additional, Fianchi, Luana, additional, Rahimli, Laman, additional, Tarantini, Giuseppe, additional, Grifoni, Federica Irene, additional, Labrador, Jorge, additional, Cordoba, Raul, additional, Lopez-Garcia, Alberto, additional, Fracchiolla, Nicola Stefano, additional, Farina, Francesca, additional, Cornely, Oliver A., additional, and Pagano, Livio, additional

Published
2023
Full Text
View/download PDF

12. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

Author

Bassan, Renato, primary, Chiaretti, Sabina, additional, Della Starza, Irene, additional, Spinelli, Orietta, additional, Santoro, Alessandra, additional, Paoloni, Francesca Paola, additional, Messina, Monica, additional, Elia, Loredana, additional, De Propris, Maria Stefania Stefania, additional, Scattolin, Anna Maria, additional, Audisio, Ernesta, additional, Marbello, Laura, additional, Borlenghi, Erika, additional, Zappasodi, Patrizia, additional, Mauro, Elisa, additional, Martinelli, Giovanni, additional, Mattei, Daniele, additional, Fracchiolla, Nicola Stefano, additional, Bocchia, Monica, additional, De Fabritiis, Paolo, additional, Bonifacio, Massimiliano, additional, Candoni, Anna, additional, Cassibba, Vincenzo, additional, Di Bartolomeo, Paolo, additional, Latte, Giancarlo, additional, Trappolini, Silvia, additional, Guarini, Anna Rita, additional, Vitale, Antonella, additional, Fazi, Paola, additional, Piciocchi, Alfonso, additional, Rambaldi, Alessandro, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

14. Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.

Author

Cardinali, Deborah, Beldinanzi, Marco, Ansuinelli, Michela, Elia, Loredana, Della Starza, Irene, Bellomarino, Vittorio, Matarazzo, Mabel, Di Trani, Mariangela, Cola, Mattia, Salutari, Prassede, Cedrone, Michele, Bassan, Renato, De Gobbi, Marco, Della Porta, Matteo Giovanni, De Simone, Mariacarla, Alati, Caterina, Fracchiolla, Nicola Stefano, Lunghi, Monia, Intermesoli, Tamara, and Cardinali, Valeria

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, PROTEIN-tyrosine kinase inhibitors, DISEASE relapse
Abstract

This document discusses the use of digital droplet PCR (ddPCR) as a tool for detecting the T315I mutation in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The T315I mutation is associated with resistance to tyrosine kinase inhibitors (TKIs), which are commonly used in the treatment of Ph+ ALL. The study found that ddPCR was as sensitive as Sanger sequencing (SS) for detecting the T315I mutation, and in some cases, ddPCR was more sensitive than SS at low levels of minimal residual disease (MRD). This suggests that ddPCR could be a valuable tool for anticipating relapse in Ph+ ALL patients. The article discusses the use of digital droplet PCR (ddPCR) as a sensitive tool for detecting minimal residual disease (MRD) and predicting relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study found that ddPCR was at least as sensitive as real-time quantitative PCR (RQ-PCR) in detecting MRD and could identify mutations in the BCR-ABL1 kinase domain (KD) before an increase in MRD levels. The authors suggest that ddPCR could be used to guide treatment decisions and improve outcomes for Ph+ ALL patients. Further research is needed to validate these findings and determine the clinical value of ddPCR in this context. [Extracted from the article]

Published
2023
Full Text
View/download PDF

15. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

Author

Bassan, Renato, Chiaretti, Sabina, Della Starza, Irene, Spinelli, Orietta, Santoro, Alessandra, Paoloni, Francesca Paola, Messina, Monica, Elia, Loredana, De Propris, Maria Stefania Stefania, Scattolin, Anna Maria, Audisio, Ernesta, Marbello, Laura, Borlenghi, Erika, Zappasodi, Patrizia, Mauro, Elisa, Martinelli, Giovanni, Mattei, Daniele, Fracchiolla, Nicola Stefano, Bocchia, Monica, De Fabritiis, Paolo, Bonifacio, Massimiliano, Candoni, Anna, Cassibba, Vincenzo, Di Bartolomeo, Paolo, Latte, Giancarlo, Trappolini, Silvia, Guarini, Anna Rita, Vitale, Antonella, Fazi, Paola, Piciocchi, Alfonso, Rambaldi, Alessandro, and Foà, Robin

Subjects
Settore MED/15
Published
2023

18. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Author

Merli, Michele, Ferrarini, Isacco, Merli, Francesco, Busca, Alessandro, Mina, Roberto, Falini, Brunangelo, Bruna, Riccardo, Cairoli, Roberto, Marchetti, Monia, Romano, Alessandra, Cavo, Michele, Arcaini, Luca, Trentin, Livio, Cattaneo, Chiara, Derenzini, Enrico, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Scattolin, Annamaria, Billio, Atto, Bocchia, Monica, Massaia, Massimo, Gambacorti-Passerini, Carlo, Mauro, Francesca Romana, Gentile, Massimo, Mohamed, Sara, Della Porta, Matteo Giovanni, Coviello, Elisa, Cilloni, Daniela, Visani, Giuseppe, Federici, Augusto Bramante, Tisi, Maria Chiara, Cudillo, Laura, Galimberti, Sara, Gherlinzoni, Filippo, Pagano, Livio, Guidetti, Anna, Bertù, Lorenza, Corradini, Paolo, Passamonti, Francesco, Visco, Carlo, Pagano, Livio (ORCID:0000-0001-8287-928X), Merli, Michele, Ferrarini, Isacco, Merli, Francesco, Busca, Alessandro, Mina, Roberto, Falini, Brunangelo, Bruna, Riccardo, Cairoli, Roberto, Marchetti, Monia, Romano, Alessandra, Cavo, Michele, Arcaini, Luca, Trentin, Livio, Cattaneo, Chiara, Derenzini, Enrico, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Scattolin, Annamaria, Billio, Atto, Bocchia, Monica, Massaia, Massimo, Gambacorti-Passerini, Carlo, Mauro, Francesca Romana, Gentile, Massimo, Mohamed, Sara, Della Porta, Matteo Giovanni, Coviello, Elisa, Cilloni, Daniela, Visani, Giuseppe, Federici, Augusto Bramante, Tisi, Maria Chiara, Cudillo, Laura, Galimberti, Sara, Gherlinzoni, Filippo, Pagano, Livio, Guidetti, Anna, Bertù, Lorenza, Corradini, Paolo, Passamonti, Francesco, Visco, Carlo, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

COVID-19, the disease caused by SARS-CoV-2, is still afflicting thousands of people across the globe. Few studies on COVID-19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID-19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38-94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID-19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID-19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow-up of 42 days (IQR 24-96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020-22 June 2020) and second wave (23 June 2020-1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03-3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23-4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04-2.84, p = 0.04) and COVID-19 severity (severe: HR 5.66, 95% CI 2.62-12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93-36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID-related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters.

Published
2023

20. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study

Author

Dargenio, Michelina, primary, Bonifacio, Massimiliano, additional, Chiaretti, Sabina, additional, Vitale, Antonella, additional, Fracchiolla, Nicola Stefano, additional, Papayannidis, Cristina, additional, Giglio, Fabio, additional, Salutari, Prassede, additional, Audisio, Ernesta, additional, Scappini, Barbara, additional, Zappasodi, Patrizia, additional, Defina, Marzia, additional, Forghieri, Fabio, additional, Scattolin, Anna Maria, additional, Todisco, Elisabetta, additional, Lunghi, Monia, additional, Guolo, Fabio, additional, Del Principe, Maria Ilaria, additional, Annunziata, Mario, additional, Lazzarotto, Davide, additional, Cedrone, Michele, additional, Pasciolla, Crescenza, additional, Imovilli, Annalisa, additional, Tanasi, Ilaria, additional, Trappolini, Silvia, additional, Cerrano, Marco, additional, La Starza, Roberta, additional, Krampera, Mauro, additional, Di Renzo, Nicola, additional, Candoni, Anna, additional, Pizzolo, Giovanni, additional, Ferrara, Felicetto, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

21. Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group

Author

Defina, Marzia, primary, Lazzarotto, Davide, additional, Guolo, Fabio, additional, Minetto, Paola, additional, Fracchiolla, Nicola Stefano, additional, Giglio, Fabio, additional, Forghieri, Fabio, additional, Vitale, Antonella, additional, Chiaretti, Sabina, additional, Papayannidis, Cristina, additional, Piccini, Matteo, additional, Mulè, Antonino, additional, Bocchia, Monica, additional, Leoncin, Matteo, additional, Gurrieri, Carmela, additional, Aprile, Lara, additional, Lunghi, Monia, additional, Bonifacio, Massimiliano, additional, Pasciolla, Crescenza, additional, Cerrano, Marco, additional, Fumagalli, Monica, additional, Foà, Robin, additional, and Candoni, Anna, additional

Published
2022
Full Text
View/download PDF

22. SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort

Author

Merli, Michele, primary, Ferrarini, Isacco, additional, Merli, Francesco, additional, Busca, Alessandro, additional, Mina, Roberto, additional, Falini, Brunangelo, additional, Bruna, Riccardo, additional, Cairoli, Roberto, additional, Marchetti, Monia, additional, Romano, Alessandra, additional, Cavo, Michele, additional, Arcaini, Luca, additional, Trentin, Livio, additional, Cattaneo, Chiara, additional, Derenzini, Enrico, additional, Fracchiolla, Nicola Stefano, additional, Marchesi, Francesco, additional, Scattolin, Annamaria, additional, Billio, Atto, additional, Bocchia, Monica, additional, Massaia, Massimo, additional, Gambacorti‐Passerini, Carlo, additional, Mauro, Francesca Romana, additional, Gentile, Massimo, additional, Mohamed, Sara, additional, Della Porta, Matteo Giovanni, additional, Coviello, Elisa, additional, Cilloni, Daniela, additional, Visani, Giuseppe, additional, Federici, Augusto Bramante, additional, Tisi, Maria Chiara, additional, Cudillo, Laura, additional, Galimberti, Sara, additional, Gherlinzoni, Filippo, additional, Pagano, Livio, additional, Guidetti, Anna, additional, Bertù, Lorenza, additional, Corradini, Paolo, additional, Passamonti, Francesco, additional, and Visco, Carlo, additional

Published
2022
Full Text
View/download PDF

23. Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse

Author

Serpenti, Fabio, primary, Sciumè, Mariarita, additional, Galassi, Giulia, additional, Saporiti, Giorgia, additional, Grifoni, Federica, additional, Rampi, Nicolò, additional, Cavallaro, Francesca, additional, Barbullushi, Kordelia, additional, Tagliaferri, Elena, additional, Goldaniga, Maria, additional, Baldini, Luca, additional, Fracchiolla, Nicola Stefano, additional, and Onida, Francesco, additional

Published
2022
Full Text
View/download PDF

24. Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

Author

Messina, Monica, primary, Piciocchi, Alfonso, additional, Ottone, Tiziana, additional, Paolini, Stefania, additional, Papayannidis, Cristina, additional, Lessi, Federica, additional, Fracchiolla, Nicola Stefano, additional, Forghieri, Fabio, additional, Candoni, Anna, additional, Mengarelli, Andrea, additional, Martelli, Maria Paola, additional, Venditti, Adriano, additional, Carella, Angelo Michele, additional, Albano, Francesco, additional, Mancini, Valentina, additional, Massimo, Bernardi, additional, Arena, Valentina, additional, Sargentini, Valeria, additional, Sciumè, Mariarita, additional, Pastore, Domenico, additional, Todisco, Elisabetta, additional, Roti, Giovanni, additional, Siragusa, Sergio, additional, Ladetto, Marco, additional, Pravato, Stefano, additional, De Bellis, Eleonora, additional, Simonetti, Giorgia, additional, Marconi, Giovanni, additional, Cerchione, Claudio, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Amadori, Sergio, additional, Martinelli, Giovanni, additional, and Voso, Maria Teresa, additional

Published
2022
Full Text
View/download PDF

26. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

Author

Cattaneo, Chiara, primary, Marchesi, Francesco, additional, Terrenato, Irene, additional, Bonuomo, Valentina, additional, Fracchiolla, Nicola Stefano, additional, Delia, Mario, additional, Criscuolo, Marianna, additional, Candoni, Anna, additional, Prezioso, Lucia, additional, Facchinelli, Davide, additional, Pasciolla, Crescenza, additional, Del Principe, Maria Ilaria, additional, Dargenio, Michelina, additional, Buquicchio, Caterina, additional, Mitra, Maria Enza, additional, Farina, Francesca, additional, Borlenghi, Erika, additional, Nadali, Gianpaolo, additional, Gagliardi, Vito Pier, additional, Fianchi, Luana, additional, Sciumè, Mariarita, additional, Menna, Pierantonio, additional, Busca, Alessandro, additional, Rossi, Giuseppe, additional, and Pagano, Livio, additional

Published
2022
Full Text
View/download PDF

27. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies:results from EPICOVIDEHA survey

Author

Pagano, Livio, Salmanton-garcía, Jon, Marchesi, Francesco, Blennow, Ola, Gomes Da Silva, Maria, Glenthøj, Andreas, Van Doesum, Jaap A., Bilgin, Yavuz M, Lopez-garcia, Alberto, Itri, Federico, Nunes Rodrigues, Raquel, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, Van Praet, Jens, Jaksic, Ozren, Valkovic, Toni, Falces-romero, Iker, Martin-perez, Sonia, Jiménez, Moraima, Davila-valls, Julio, Schonlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-velez, Irati, Fracchiolla, Nicola Stefano, Samarkos, Michail, Mendez, Gustavo-adolfo, Hernández-rivas, José-ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, Di Blasi, Roberta, Marques De Almeida, Joyce, Dargenio, Michelina, Biernat, Monika Maria, Sciumè, Mariarita, De Ramón, Cristina, De Jonge, Nick Alexander, Batinic, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández Escalada, Noemi, Zambrotta, Giovanni Paolo Maria, Sacchi, Maria Vittoria, Guidetti, Anna, Demirken, Fatih, Prezioso, Lucia, Racil, Zdenek, Nucci, Marcio, Mladenovic, Miloš, Lievin, Raphaël, Hanakova, Michaela, Grafe, Stefanie K, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adzic-vukicevic, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, Cornely, Oliver A., Pagano, Livio, Salmanton-garcía, Jon, Marchesi, Francesco, Blennow, Ola, Gomes Da Silva, Maria, Glenthøj, Andreas, Van Doesum, Jaap A., Bilgin, Yavuz M, Lopez-garcia, Alberto, Itri, Federico, Nunes Rodrigues, Raquel, Weinbergerová, Barbora, Farina, Francesca, Dragonetti, Giulia, Berg Venemyr, Caroline, Van Praet, Jens, Jaksic, Ozren, Valkovic, Toni, Falces-romero, Iker, Martin-perez, Sonia, Jiménez, Moraima, Davila-valls, Julio, Schonlein, Martin, Ammatuna, Emanuele, Meers, Stef, Delia, Mario, Stojanoski, Zlate, Nordlander, Anna, Lahmer, Tobias, Pinczés, László Imre, Buquicchio, Caterina, Piukovics, Klára, Ormazabal-velez, Irati, Fracchiolla, Nicola Stefano, Samarkos, Michail, Mendez, Gustavo-adolfo, Hernández-rivas, José-ángel, Espigado, Ildefonso, Cernan, Martin, Petzer, Verena, Lamure, Sylvain, Di Blasi, Roberta, Marques De Almeida, Joyce, Dargenio, Michelina, Biernat, Monika Maria, Sciumè, Mariarita, De Ramón, Cristina, De Jonge, Nick Alexander, Batinic, Josip, Aujayeb, Avinash, Marchetti, Monia, Fouquet, Guillemette, Fernández Escalada, Noemi, Zambrotta, Giovanni Paolo Maria, Sacchi, Maria Vittoria, Guidetti, Anna, Demirken, Fatih, Prezioso, Lucia, Racil, Zdenek, Nucci, Marcio, Mladenovic, Miloš, Lievin, Raphaël, Hanakova, Michaela, Grafe, Stefanie K, Sili, Uluhan, Machado, Marina, Cattaneo, Chiara, Adzic-vukicevic, Tatjana, Verga, Luisa, Labrador, Jorge, Rahimli, Laman, Bonanni, Matteo, Passamonti, Francesco, Pagliuca, Antonio, Corradini, Paolo, Hoenigl, Martin, Koehler, Philipp, Busca, Alessandro, and Cornely, Oliver A.

Abstract

Limited data have been published on the epidemiology and outcomes of breakthrough COVID-19 in patients with hematological malignancy (HM) after anti-SARS-CoV-2 vaccination. Adult HM who received at least one dose of anti-SARS-CoV-2 vaccine and diagnosed with breakthrough COVID-19 between January 2021 and March 2022 and registered in EPICOVIDEHA were included in this analysis. A total of 1548 cases were included, mainly with lymphoid malignancies (1181 cases, 76%). After viral genome sequencing in 753 cases (49%), Omicron variant was prevalent (517, 68.7%). Most of the patients received at least two vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received specific treatment for COVID-19. After 30-days follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with Omicron variant was of 7.9%, comparable to that reported for the other variants. The 30-day mortality rate was significantly lower than in the pre-vaccine era (31%). In the univariable analysis, older age (p<0.001), active HM (p<0.001), severe and critical COVID-19 (p=0.007 and p<0.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (p<0.001). In the multivariable model, older age, active disease, critical COVID-19 and at least 2-3 comorbidities were correlated with a higher mortality, whereas the administration of monoclonal antibodies, alone (p<0.001) or combined with antivirals (p=0.009), was observed protective. While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA (www.clinicaltrials.gov; National Clinical Trials identifier NCT04733729) is an international open web-based regi

Published
2022

28. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study.

Author

Dargenio, Michelina, Bonifacio, Massimiliano, Chiaretti, Sabina, Vitale, Antonella, Fracchiolla, Nicola Stefano, Papayannidis, Cristina, Giglio, Fabio, Salutari, Prassede, Audisio, Ernesta, Scappini, Barbara, Zappasodi, Patrizia, Defina, Marzia, Forghieri, Fabio, Scattolin, Anna Maria, Todisco, Elisabetta, Lunghi, Monia, Guolo, Fabio, Del Principe, Maria Ilaria, Annunziata, Mario, and Lazzarotto, Davide

Subjects
CENTRAL nervous system, LYMPHOBLASTIC leukemia, ACUTE leukemia, TREATMENT effectiveness, SPINAL infusions
Abstract

Summary: Within the Campus ALL network we analyzed the incidence, characteristics, treatment and outcome of a central nervous system (CNS) relapse in 1035 consecutive adult acute lymphoblastic leukemia (ALL) patients treated frontline with pediatric‐inspired protocols between 2009 and 2020. Seventy‐one patients (6.8%) experienced a CNS recurrence, more frequently in T‐ (28/278; 10%) than in B‐ALL (43/757; 5.7%) (p = 0.017). An early CNS relapse—< 12 months from diagnosis—was observed in 41 patients. In multivariate analysis, risk factors for early CNS relapse included T‐cell phenotype (p = <0.001), hyperleucocytosis >100 × 109/L (p<0.001) and male gender (p = 0.015). Treatment was heterogeneous, including chemotherapy, radiotherapy, intrathecal therapy and novel agents. A complete remission (CR) was obtained in 39 patients (55%) with no differences among strategies. After CR, 26 patients underwent an allogenic transplant, with a significant overall survival benefit compared to non‐transplanted patients (p = 0.012). After a median observation of 8 months from CNS relapse, 23 patients (32%) were alive. In multivariate analysis, the time to CNS relapse was the strongest predictor of a lower 2‐year post‐relapse survival (p<0.001). In conclusion, in adult ALL the outcome after a CNS relapse remains very poor. Effective CNS prophylaxis remains the best approach and allogenic transplant should be pursued when possible. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study

Author

Cerrano, Marco, Bonifacio, Massimiliano, Olivi, Matteo, Curti, Antonio, Malagola, Michele, Dargenio, Michelina, Scattolin, Anna Maria, Papayannidis, Cristina, Forghieri, Fabio, Gurrieri, Carmela, Tanasi, Ilaria, Zappasodi, Patrizia, La Starza, Roberta, Fracchiolla, Nicola Stefano, Chiusolo, Patrizia, Giaccone, Luisa, Del Principe, Maria Ilaria, Giglio, Fabio, Defina, Marzia, Favre, Claudio, Rizzari, Carmelo, Castella, Barbara, Pizzolo, Giovanni, Ferrara, Felicetto, Chiaretti, Sabina, and Foà, Robin

Subjects
Not available, Settore MED/15
Published
2022

31. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, Marco, primary, Bonifacio, Massimiliano, additional, Olivi, Matteo, additional, Curti, Antonio, additional, Malagola, Michele, additional, Dargenio, Michelina, additional, Scattolin, Anna Maria, additional, Papayannidis, Cristina, additional, Forghieri, Fabio, additional, Gurrieri, Carmela, additional, Tanasi, Ilaria, additional, Zappasodi, Patrizia, additional, La Starza, Roberta, additional, Fracchiolla, Nicola Stefano, additional, Chiusolo, Patrizia, additional, Giaccone, Luisa, additional, Del Principe, Maria Ilaria, additional, Giglio, Fabio, additional, Defina, Marzia, additional, Favre, Claudio, additional, Rizzari, Carmelo, additional, Castella, Barbara, additional, Pizzolo, Giovanni, additional, Ferrara, Felicetto, additional, Chiaretti, Sabina, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

32. Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy

Author

Saccon, Elisa, Bandera, Alessandra, Sciumè, Mariarita, Mikaeloff, Flora, Lashari, Abid A., Aliberti, Stefano, Sachs, Michael C., Billi, Filippo, Blasi, Francesco, Gabriel, Erin E., Costantino, Giorgio, De Roberto, Pasquale, Krishnan, Shuba, Gori, Andrea, Peyvandi, Flora, Scudeller, Luigia, Canetta, Ciro, Lorson, Christian L., Valenti, Luca, Singh, Kamal, Baldini, Luca, Fracchiolla, Nicola Stefano, and Neogi, Ujjwal

Subjects
Aged, 80 and over, Male, SARS-CoV-2, fatal outcome, COVID-19, Observation, Comorbidity, Middle Aged, Prognosis, metabolomics, Microbiology, QR1-502, predictive biomarkers, Italy, Metabolome, Humans, Female, Energy Metabolism, Biomarkers, Blood Chemical Analysis, Aged, Retrospective Studies
Abstract

In one year of the coronavirus disease 2019 (COVID-19) pandemic, many studies have described the different metabolic changes occurring in COVID-19 patients, linking these alterations to the disease severity. However, a complete metabolic signature of the most severe cases, especially those with a fatal outcome, is still missing. Our study retrospectively analyzes the metabolome profiles of 75 COVID-19 patients with moderate and severe symptoms admitted to Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Lombardy Region, Italy) following SARS-CoV-2 infection between March and April 2020. Italy was the first Western country to experience COVID-19, and the Lombardy Region was the epicenter of the Italian COVID-19 pandemic. This cohort shows a higher mortality rate compared to others; therefore, it represents a unique opportunity to investigate the underlying metabolic profiles of the first COVID-19 patients in Italy and to identify the potential biomarkers related to the disease prognosis and fatal outcome. IMPORTANCE Understanding the metabolic alterations occurring during an infection is a key element for identifying potential indicators of the disease prognosis, which are fundamental for developing efficient diagnostic tools and offering the best therapeutic treatment to the patient. Here, exploiting high-throughput metabolomics data, we identified the first metabolic profile associated with a fatal outcome, not correlated with preexisting clinical conditions or the oxygen demand at the moment of diagnosis. Overall, our results contribute to a better understanding of COVID-19-related metabolic disruption and may represent a useful starting point for the identification of independent prognostic factors to be employed in therapeutic practice.

Published
2021

35. Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy)

Author

Fattizzo, Bruno, Giannotta, Juri Alessandro, Barcellini, Wilma, Barbanti, Maria Chiara, Bucelli, Cristina, Cassin, Ramona, Cattaneo, Daniele, Cavallaro, Francesca, Ferla, Valeria, Fracchiolla, Nicola Stefano, Freyrie, Alessandra, Galassi, Giulia, Goldaniga, Maria Cecilia, Grifoni, Federica Irene, Iurlo, Alessandra, Mangiameli, Giancarlo, Mattiello, Veronica, Meli, Mario, Neri, Antonino, Noto, Alessandro, Onida, Francesco, Ottani, Laura, Pasquale, Raffaella, Pettine, Loredana, Pompa, Alessandra, Reda, Gianluigi, Rossi, Francesca Gaia, Saporiti, Giorgia Natascia, Sciumè, Mariarita, Tagliaferri, Elena, and Baldini, Luca

Published
2020
Full Text
View/download PDF

36. A distinct metabolic profile associated with a fatal outcome in COVID-19 patients during early epidemic in Italy

Author

Saccon, Elisa, primary, Bandera, Alessandra, additional, Sciumè, Mariarita, additional, Mikeloff, Flora, additional, Lashari, Abid Ali, additional, Aliberti, Stefano, additional, Sachs, Michael, additional, Billi, Filippo, additional, Blasi, Francesco, additional, Gabriel, Erin, additional, Costantino, Giorgio, additional, De Roberto, Pasquale, additional, Krishnan, Shuba, additional, Gori, Andrea, additional, Peyvandi, Flora, additional, Scudeller, Luigia, additional, Lorson, Christian L., additional, Valenti, Luca, additional, Singh, Kamal, additional, Baldini, Luca, additional, Fracchiolla, Nicola Stefano, additional, and Neogi, Ujjwal, additional

Published
2021
Full Text
View/download PDF

43. An Unusual Coexistence of Primary Central Nervous System Non-Hodgkin’s Lymphoma and Acute Promyelocytic Leukemia

Author

Fracchiolla, Nicola Stefano, Sciumè, Mariarita, Cernuschi, Giulia, and Cortelezzi, Agostino

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

Acute promyelocytic leukemia and primary central nervous system lymphoma are uncommon hematological malignancies. The co-occurrence of acute myeloid leukemia with various lymphoproliferative diseases is an extremely rare condition, especially in the absence of previous chemotherapy or radiotherapy. Herein, we provide a comprehensive characterization of a patient with concomitant diagnosis of extranodal high-grade non-Hodgkin B-cell neoplasm confined to the central nervous system and acute promyelocytic leukemia. We describe the efficacy and feasibility of the consecutive use of all-trans retinoic acid and arsenic trioxide-containing regimen for the treatment of promyelocytic leukemia and high-dose methotrexate plus cytarabine to treat lymphoproliferative involvement of the central nervous system.

Published
2018
Full Text
View/download PDF

44. Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study

Author

Fracchiolla, Nicola Stefano, primary, Sciumè, Mariarita, additional, Orofino, Nicola, additional, Guidotti, Francesca, additional, Grancini, Anna, additional, Cavalca, Fabrizio, additional, Freyrie, Alessandra, additional, Goldaniga, Maria Cecilia, additional, Consonni, Dario, additional, Mattiello, Veronica, additional, Pettine, Loredana, additional, and Cortelezzi, Agostino, additional

Published
2019
Full Text
View/download PDF

45. A case report of systemic mastocytosis associated with multiple hematologic non–mast cell lineage diseases

Author

Grifoni, Federica Irene, primary, Sciumè, Mariarita, additional, Pravettoni, Valerio, additional, Ulivieri, Fabio Massimo, additional, Muratori, Simona, additional, Fracchiolla, Nicola Stefano, additional, Tagliaferri, Elena, additional, Gianelli, Umberto, additional, Migliorini, Anna Chiara, additional, Cro, Lilla, additional, Pacilli, Annalisa, additional, Mannelli, Francesco, additional, and Baldini, Luca, additional

Published
2019
Full Text
View/download PDF

47. P1686: LONG‐TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY.

Author

Efficace, Fabio, Cannella, Laura, Thomas, Xavier, Yüksel, Meltem Kurt, Trisolini, Silvia Maria, Brini, Alberto, Audisio, Ernesta, Maurillo, Luca, Lemoli, Roberto M., Imovilli, Annalisa, Panovska‐Stavridis, Irina, Pagano, Livio, Ciccone, Maria, Filardi, Nunzio, Fracchiolla, Nicola Stefano, Vallisa, Daniele, Crugnola, Monica, Cascavilla, Nicola, Skerget, Matevz, and Vignetti, Marco

Published
2023
Full Text
View/download PDF

48. Rhodotorula infection in haematological patient: Risk factors and outcome

Author

Potenza, Leonardo, Chitasombat, Maria N., Klimko, Nikolay, Bettelli, Francesca, Dragonetti, Giulia, Del Principe, Maria Ilaria, Nucci, Marcio, Busca, Alessandro, Fracchiolla, Nicola Stefano, Sciumè, Mariarita, Spolzino, Angelica, Delia, Mario, Mancini, Valentina, Nadali, Gian Paolo, Dargenio, Michela, Shadrivova, Olga, Bacchelli, Federico, Aversa, Franco, Sanguinetti, Maurizio, Luppi, Mario, Kontoyiannis, Dimitrios P., Pagano, Livio, Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Pagano, Livio (ORCID:0000-0001-8287-928X), Potenza, Leonardo, Chitasombat, Maria N., Klimko, Nikolay, Bettelli, Francesca, Dragonetti, Giulia, Del Principe, Maria Ilaria, Nucci, Marcio, Busca, Alessandro, Fracchiolla, Nicola Stefano, Sciumè, Mariarita, Spolzino, Angelica, Delia, Mario, Mancini, Valentina, Nadali, Gian Paolo, Dargenio, Michela, Shadrivova, Olga, Bacchelli, Federico, Aversa, Franco, Sanguinetti, Maurizio, Luppi, Mario, Kontoyiannis, Dimitrios P., Pagano, Livio, Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Background: Rhodotorula spp are uncommon yeasts able to cause infections with high mortality rates. Rhodotorula infections have been associated with the presence of central venous catheter (CVC), immunosuppression, exposure to antifungals and the presence of either solid or haematologic malignancies. However, in this latter setting, only a few cases have so far been reported. Objectives: We have conducted a survey for Rhodotorula infections in haematologic patients. Methods: Patients’ clinical and microbiological data were collected and correlated to the outcome. Results: A total of 27 cases were detected from 13 tertiary care hospitals. About 78% and 89% of patients had acute leukaemia and CVC. About 70% of patients were exposed to prophylaxis with azoles, mainly posaconazole (37%), 59% were severely neutropenic and 37% underwent allogeneic stem cell transplantation (alloSCT). The most frequent treatments were liposomal amphotericin B (L-AmB) and CVC removal in 17 and 16 patients, respectively. One month post-diagnosis, mortality was 26% and was associated with the presence of mucositis (P = 0.034). Conclusions: Our study shows that Rhodotorula spp should be considered as aetiologic agents of breakthrough infections in acute leukaemia patients with a CVC, mucositis, who receive prophylaxis with azoles, including posaconazole, and/or undergo alloSCT. Prompt measures, such as L-AmB administration and CVC removal, should be carried out to avoid the high mortality risk of Rhodotorula infections.

Published
2018

49. SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders

Author

Busca, Alessandro, Cesaro, Simone, Teofili, Luciana, Delia, Mario, Cattaneo, Chiara, Criscuolo, Marianna, Marchesi, Francesco, Fracchiolla, Nicola Stefano, Valentini, Caterina Giovanna, Farina, Francesca, Di Blasi, Roberta, Prezioso, Lucia, Spolzino, Angelica, Candoni, Anna, del Principe, Maria Ilaria, Verga, Luisa, Nosari, Annamaria, Aversa, Franco, Pagano, Livio, Teofili, Luciana (ORCID:0000-0002-7214-1561), Pagano, Livio (ORCID:0000-0001-8287-928X), Busca, Alessandro, Cesaro, Simone, Teofili, Luciana, Delia, Mario, Cattaneo, Chiara, Criscuolo, Marianna, Marchesi, Francesco, Fracchiolla, Nicola Stefano, Valentini, Caterina Giovanna, Farina, Francesca, Di Blasi, Roberta, Prezioso, Lucia, Spolzino, Angelica, Candoni, Anna, del Principe, Maria Ilaria, Verga, Luisa, Nosari, Annamaria, Aversa, Franco, Pagano, Livio, Teofili, Luciana (ORCID:0000-0002-7214-1561), and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Introduction: The rapid spread of severe infections mainly due to resistant pathogens, justifies the search for therapies aiming to restore immune functions severely compromised in patients with hematologic malignancies. Areas covered: The present review summarizes the current knowledge on the role of granulocyte transfusions and colony-stimulating factors as treatment strategy for hematologic patients with serious infectious complications. In addition, a survey among 21 hematologic centers, to evaluate the clinical practice for the use of G-CSF originator and biosimilars was performed. Expert commentary: Granulocyte transfusions with a target dose of at least 1.5-3 × 108cells/kg, may be considered as an approach to bridge the gap between marrow suppression and recovery of granulocytes. G-CSF shortens the period of neutropenia, the hospitalization, the use of antibiotics and the rate of febrile neutropenia (FN) in adult and pediatric patients with non-Hodgkin lymphoma, and in adults with acute myeloid leukemia where these advantages nevertheless, did not translate into a clinical benefit. G-CSF biosimilar showed equivalence or non-inferiority to filgrastim. There are no data supporting the use of GM-CSF, eltrombopag and erythropoietin for preventing or treating infectious complications in patients with hematologic disorders.

Published
2018

50. Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications

Author

Fracchiolla, Nicola Stefano, Fattizzo, Bruno, and Cortelezzi, Agostino

Subjects
Article Subject
Abstract

The importance of the bone marrow microenvironment forming the so-called niche in physiologic hemopoiesis is largely known, and recent evidences support the presence of stromal alterations from the molecular to the cytoarchitectural level in hematologic malignancies. Various alterations in cell adhesion, metabolism, cytokine signaling, autophagy, and methylation patterns of tumor-derived mesenchymal stem cells have been demonstrated, contributing to the genesis of a leukemic permissive niche. This niche allows both the ineffective haematopoiesis typical of myelodysplastic syndromes and the differentiation arrest, proliferation advantage, and clone selection which is the hallmark of acute myeloid leukemia. Furthermore, the immune system, both adaptive and innate, encompassing mesenchymal-derived cells, has been shown to take part to the leukemic niche. Here, we critically review the state of art about mesenchymal stem cell role in myelodysplastic syndromes and acute myeloid leukemia, focusing on immune escaping mechanisms as a target for available and future anticancer therapies.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results